Swiss Life Asset Management Ltd Purchases 32,202 Shares of Zoetis Inc. $ZTS

Swiss Life Asset Management Ltd boosted its position in shares of Zoetis Inc. (NYSE:ZTS) by 22.1% in the 4th quarter, according to its most recent filing with the Securities and Exchange Commission. The fund owned 177,893 shares of the company’s stock after purchasing an additional 32,202 shares during the quarter. Swiss Life Asset Management Ltd’s holdings in Zoetis were worth $22,382,000 as of its most recent filing with the Securities and Exchange Commission.

Several other institutional investors and hedge funds have also recently added to or reduced their stakes in the company. Vanguard Group Inc. raised its holdings in Zoetis by 12.9% during the 4th quarter. Vanguard Group Inc. now owns 47,780,974 shares of the company’s stock worth $6,011,802,000 after purchasing an additional 5,474,210 shares during the last quarter. Nordea Investment Management AB increased its stake in shares of Zoetis by 79.2% in the 4th quarter. Nordea Investment Management AB now owns 4,932,787 shares of the company’s stock valued at $622,222,000 after acquiring an additional 2,179,578 shares during the last quarter. Mitsubishi UFJ Asset Management Co. Ltd. increased its stake in shares of Zoetis by 14.6% in the 3rd quarter. Mitsubishi UFJ Asset Management Co. Ltd. now owns 4,312,779 shares of the company’s stock valued at $631,046,000 after acquiring an additional 550,859 shares during the last quarter. Alliancebernstein L.P. increased its stake in shares of Zoetis by 13.3% in the 3rd quarter. Alliancebernstein L.P. now owns 4,241,357 shares of the company’s stock valued at $620,595,000 after acquiring an additional 496,320 shares during the last quarter. Finally, Fundsmith LLP increased its stake in shares of Zoetis by 25.3% in the 3rd quarter. Fundsmith LLP now owns 3,615,131 shares of the company’s stock valued at $528,966,000 after acquiring an additional 730,300 shares during the last quarter. 92.80% of the stock is owned by institutional investors.

Zoetis Price Performance

Shares of ZTS opened at $76.62 on Tuesday. The company has a debt-to-equity ratio of 2.80, a quick ratio of 1.91 and a current ratio of 3.15. The stock has a 50 day simple moving average of $116.50 and a 200 day simple moving average of $122.77. Zoetis Inc. has a 52-week low of $76.38 and a 52-week high of $172.23. The firm has a market capitalization of $32.12 billion, a PE ratio of 12.71, a P/E/G ratio of 1.29 and a beta of 0.87.

Zoetis (NYSE:ZTS) last issued its quarterly earnings data on Thursday, May 7th. The company reported $1.53 earnings per share (EPS) for the quarter, missing the consensus estimate of $1.60 by ($0.07). Zoetis had a net margin of 27.80% and a return on equity of 66.85%. The business had revenue of $2.26 billion during the quarter, compared to analyst estimates of $2.30 billion. During the same quarter in the prior year, the firm posted $1.48 earnings per share. Zoetis’s revenue for the quarter was up 2.9% compared to the same quarter last year. Zoetis has set its FY 2026 guidance at 6.850-7.000 EPS. Sell-side analysts predict that Zoetis Inc. will post 6.96 EPS for the current fiscal year.

Analyst Ratings Changes

ZTS has been the subject of a number of recent analyst reports. JPMorgan Chase & Co. lowered their price target on Zoetis from $190.00 to $130.00 and set an “overweight” rating for the company in a research note on Friday. Leerink Partners reaffirmed a “market perform” rating on shares of Zoetis in a research note on Tuesday, March 10th. Citigroup initiated coverage on Zoetis in a research note on Wednesday, April 15th. They issued a “buy” rating and a $145.00 price target for the company. Bank of America upped their price target on Zoetis from $135.00 to $140.00 and gave the company a “neutral” rating in a research note on Friday, February 13th. Finally, Weiss Ratings cut Zoetis from a “hold (c-)” rating to a “sell (d+)” rating in a research note on Friday, March 27th. Seven equities research analysts have rated the stock with a Buy rating, seven have given a Hold rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat, the company has an average rating of “Hold” and an average target price of $141.25.

Zoetis Company Profile

Zoetis Inc (NYSE: ZTS) is a global animal health company that develops, manufactures and markets a broad portfolio of products and services for companion animals and livestock. The company’s offerings include pharmaceuticals, vaccines and biologics, parasiticides and anti-infectives, as well as diagnostic instruments, consumables and laboratory testing services. Zoetis serves the veterinary community, livestock producers and other animal-health customers with products designed to prevent, detect and treat disease and to support animal productivity and welfare.

Zoetis traces its roots to the animal health business of Pfizer and became an independent, publicly traded company following a 2013 separation and initial public offering.